Amicus Therapeutics, INC Schedule 13G passive stakes

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G regarding their beneficial ownership of Amicus Therapeutics, Inc. common stock.

Barclays PLC has filed a Schedule 13G reporting a 5.65% beneficial ownership stake in Amicus Therapeutics Inc.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 5.3% of Amicus Therapeutics, Inc. common stock as of March 31, 2026.

UBS Group AG has filed a Schedule 13G, reporting beneficial ownership of 17,141,817 shares, or approximately 5.5%, of Amicus Therapeutics, Inc. common stock.

Glazer Capital, LLC and Paul J. Glazer have filed an exit notice confirming they no longer beneficially own more than 5% of Amicus Therapeutics, Inc. common stock.

Vanguard Capital Management has reported beneficial ownership of 5.2% of Amicus Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Amicus Therapeutics Inc. following an internal realignment.

Wellington Management Group and its affiliates reported a 0.4% passive stake in Amicus Therapeutics, Inc. common stock.

William Blair Investment Management, LLC has reported a reduced beneficial ownership stake of 3.4% in Amicus Therapeutics, Inc. common stock.

The Vanguard Group reported a 10% beneficial ownership stake in Amicus Therapeutics Inc. common stock as of November 28, 2025.

Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 4.87% in Amicus Therapeutics, Inc., holding 15,025,000 shares.

William Blair Investment Management, LLC has reported a 5.2% beneficial ownership stake in Amicus Therapeutics, Inc. common stock.

Perceptive Advisors and related entities report a 2.4% passive beneficial ownership in Amicus Therapeutics, Inc. common stock.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported a collective beneficial ownership of 7.0% in Amicus Therapeutics, Inc. common stock.

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have reported a 6.7% passive beneficial ownership stake in Amicus Therapeutics, Inc. as of March 31, 2025.

William Blair Investment Management, LLC has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Amicus Therapeutics, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reaffirming its passive beneficial ownership of 7.4% of Amicus Therapeutics Inc.'s common stock as of March 31, 2025.

Redmile Group, LLC and its principal Jeremy C. Green have disclosed a beneficial ownership of 4.6% in Amicus Therapeutics, Inc., comprising common stock and shares issuable from warrants.

Perceptive Advisors LLC and its affiliates have reported an 8.1% beneficial ownership stake in Amicus Therapeutics, Inc., holding 24,245,952 shares as of December 31, 2024.

Wellington Management Group LLP and its affiliates have reported a 9.5% beneficial ownership stake in Amicus Therapeutics, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.3% beneficial ownership stake in Amicus Therapeutics Inc. as of December 31, 2024.